Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Guangdong Provincial People's Hospital is the lead sponsor of 84 current clinical trials in our China register. 48 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Carboplatin, Capecitabine and Aspirin. The most-studied condition is Breast Cancers.

ClinicalTrials.gov trials by status

Recruiting4857%
Not yet open2024%
Active, closed1417%
By invitation22%

Trials by phase

Not applicable3137%
Observational2226%
Phase 21518%
Phase 467%
Phase 345%
Phase 122%
Phase 1/222%
Phase EARLY_PHASE111%
Phase 2/311%

Clinical trials sponsored by Guangdong Provincial People's Hospital

84 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer NCT06734182 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Drugs: Carboplatin, Disitamab Vedotin, Envafolimab	Phase 2	Recruiting	2024-06	China
The Safety and Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy for Peritoneal Metastatic Adenocarcinoma NCT06743867 · ClinicalTrials.gov ↗ · Peritoneal Carcinoma Metastatic	Phase 1	Recruiting	2024-12	China
A Study of Chidamide With AZA in MRD Positive AML After Transplant NCT06066905 · ClinicalTrials.gov ↗ · AML, Adult, Minimal Residual Disease	Not applicable	Recruiting	2023-10	China
A Real World, Multi-centric, Observational Registry Study of Chronic Kidney Diseases NCT05188885 · ClinicalTrials.gov ↗ · Chronic Kidney Disease	Observational	Recruiting	2021-12	China
Efficacy and Safety of Qishen Yiqi Dropping Pills in Patients With Severe Pulmonary Hypertension NCT07604805 · ClinicalTrials.gov ↗ · Idiopathic Pulmonary Hypertension	Not applicable	Recruiting	2023-10	China
PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC NCT06533384 · ClinicalTrials.gov ↗ · Triple-negative Breast Cancer Drug: Capecitabine	Phase 3	Recruiting	2024-08	China
Multimodal Deep Learning Model for Multi-task Diagnosis and Triage Suggestions of Ophthalmic Diseases NCT07447973 · ClinicalTrials.gov ↗ · Anterior Segment Diseases	Observational	Recruiting	2026-03	China
Organoid-based Functional Precision Therapy for Advanced Breast Cancer NCT06102824 · ClinicalTrials.gov ↗ · HER2-negative Breast Cancer, Advanced Breast Cancer Drugs: Abraxane, Anthracycline, Capecitabine	Phase 2	Recruiting	2024-10	China
Anlotinib Combined With Doxorubicin and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma NCT06506838 · ClinicalTrials.gov ↗ · Soft Tissue Sarcoma, Doxorubicin, Radiotherapy Drug: Anlotinib	Phase 4	Recruiting	2024-08	China
Safety and Efficacy of Exercise in Type-B Aortic Dissection NCT07009067 · ClinicalTrials.gov ↗ · Type B Aortic Dissection	Not applicable	Recruiting	2025-05	China
Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma NCT05954897 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 2	Recruiting	2023-09	China
A Phase II Single-Arm Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Breast Cancer Patients NCT06811870 · ClinicalTrials.gov ↗ · Breast Cancers	Phase 1/2	Recruiting	2025-02	China
Insights Into Pediatric Pulmonary Hypertension: A Real-World Registry of Epidemiology and Outcomes NCT07495774 · ClinicalTrials.gov ↗ · Pulmonary Hypertension	Observational	Recruiting	2006-01	China
Safety and Effectiveness of Early Aspirin Administration After Mitral Valve Repair NCT06738992 · ClinicalTrials.gov ↗ · Mitral Valve Repair Surgery Drugs: Aspirin, Warfarin	Phase 4	Recruiting	2024-11	China
Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC) NCT06911606 · ClinicalTrials.gov ↗ · SCLC, Limited Stage Drugs: Cisplatin, Etoposide and carboplatin	Phase 2	Recruiting	2024-05	China
A Cohort Study on Biomarkers of Hypertension in Guangdong Province(GDP Study) NCT04212455 · ClinicalTrials.gov ↗ · Hypertension, Cardiovascular Diseases	Observational	Recruiting	2020-01	China
Correlation of Timing of Pegfilgrastim Administration and PIBP. NCT05841186 · ClinicalTrials.gov ↗ · Pegfilgrastim, Bone Pain, Chemotherapy	Not applicable	Recruiting	2023-05	China
Hyperbaric Oxygen in the Prevention of Radiation Pneumonitis NCT05189496 · ClinicalTrials.gov ↗ · Radiation Pneumonitis	Not applicable	Recruiting	2022-03	China
Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC NCT05800340 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, RET Driver Mutation, BRAF V600 Mutation Drugs: Carboplatin, Nab-paclitaxel, Pemetrexed	Phase 2	Recruiting	2023-04	China
Thrombus Aspiration in STEMI Patients With High Thrombus Burden NCT04212494 · ClinicalTrials.gov ↗ · ST-segment Elevation Myocardial Infarction (STEMI)	Not applicable	Recruiting	2020-08	China
Pembrolizumab and Induction Chemotherapy in Locally Advanced HNSCC NCT05272696 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma	Phase 2	Recruiting	2022-03	China
Correlation Between the Changes of Retinal Structure and Function and Ischemic Stroke NCT05281887 · ClinicalTrials.gov ↗ · Ischemic Stroke	Observational	Recruiting	2021-12	China
Home Blood Pressure Monitoring Registration Study in the Elderly(HOME Study) NCT04212468 · ClinicalTrials.gov ↗ · Blood Pressure	Observational	Recruiting	2020-01	China
Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial NCT07722754 · ClinicalTrials.gov ↗ · Colorectal Neoplasms Malignant, Neoplasm, Metastatic Drugs: Bevacizumab, Cetuximab, Irinotecan	Phase 2	Recruiting	2026-07	China
Association Between RVT and Prognosis After Neoadjuvant Targeted Therapy in EGFR NSCLC NCT06771960 · ClinicalTrials.gov ↗ · Lung Cancer (NSCLC)	Observational	Recruiting	2025-02	China
International Big Data Centre in Emergency Medicine NCT05616416 · ClinicalTrials.gov ↗ · Emergency Medicine	Observational	Recruiting	2011-01	China
Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML NCT06451861 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia Drugs: Azacitidine, Chidamide, Cytarabine	Phase 2	Recruiting	2024-08	China
Weight Loss Via Intelligent Guidance in Patients With Coronary Heart Disease and Obesity: a Randomized Clinical Trial NCT07514611 · ClinicalTrials.gov ↗ · CHD, Overweight or Obese	Not applicable	Recruiting	2026-04	China
Predictive Value of Non-fasting Blood Lipid Levels for Cardiovascular Events in Community Population(PICC Study) NCT04212520 · ClinicalTrials.gov ↗ · Lipid	Observational	Recruiting	2020-01	China
Catheter Ablation Plus LAAO Versus Anticoagulation in Frail Elderly Patients With Atrial Fibrillation NCT07441382 · ClinicalTrials.gov ↗ · Atrial Fibrillation (AF), Stroke, Hemorrhage	Not applicable	Recruiting	2026-03	China
Yiyuancong for the Treatment of Sudden Sensorineural Hearing Loss NCT07505667 · ClinicalTrials.gov ↗ · Sudden Hearing Loss, Sensorineural Hearing Loss	Not applicable	Recruiting	2025-11	China
EACH-ADHF: Early Comprehensive Rehabilitation in Patients With ADHF NCT06161987 · ClinicalTrials.gov ↗ · Acute Decompensated Heart Failure	Not applicable	Recruiting	2023-12	China
NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis NCT06676631 · ClinicalTrials.gov ↗ · Refractory Systemic Lupus Erythematosus, Refractory Lupus Nephritis Drug: Rituximab	Phase 1	Recruiting	2025-02	China
Short-term Effects of Preoperative Exercise in Moderate-to-high Perioperative Risk Lung Cancer Patients NCT06215326 · ClinicalTrials.gov ↗ · Lung Cancer	Not applicable	Recruiting	2024-01	China
A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer NCT06758544 · ClinicalTrials.gov ↗ · Pancreatic Cancer Drug: Oncolytic virus VRT106	Phase 1/2	Recruiting	2025-03	China
Efficacy and Safety of Nalfurafine Hydrochloride ODT for Moderate-to-Severe Pruritus in Patients on Peritoneal Dialysis NCT07098351 · ClinicalTrials.gov ↗ · Adverse Event, Peritoneal Dialysis, Moderate-to-severe Pruritus	Not applicable	Recruiting	2025-08	China
A Novel Intraoperative Fluorescence-guided System for Evaluating Margins During Breast-conserving Surgery for Breast Cancer NCT07352930 · ClinicalTrials.gov ↗ · Breast-Conserving Surgery	Not applicable	Recruiting	2026-04	China
Association of Inpatient Blood Pressure Levels With In-hospital Adverse Events(APPLE Study) NCT04226612 · ClinicalTrials.gov ↗ · Blood Pressure	Observational	Recruiting	2000-01	China
Community Exercise Treating Effect on Cardiopulmonary Disease Patients NCT07154355 · ClinicalTrials.gov ↗ · Coronary Heart Disease (CHD), Heart Failure, Cardiomyopathy	Not applicable	Recruiting	2025-01	China
The Safety and Efficacy of Autologous Transfusion in Spinal Surgery for Lung Cancer With Spinal Metastasis NCT06244264 · ClinicalTrials.gov ↗ · Spinal Metastases, Blood Transfusion Complication, Lung Cancer	Not applicable	Recruiting	2024-03	China
A Study of Pegmolesatide of in Dialysis Chronic Kidney Disease (CKD) Patients With Anemia Treated With Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI) NCT07136792 · ClinicalTrials.gov ↗ · Renal Anemia of Chronic Kidney Disease	Not applicable	Recruiting	2025-09	China
Effect of Exercise on Tapering Antipsychotics in Patients With Psycho-cardiological Disease(EXTRA-study) NCT07025590 · ClinicalTrials.gov ↗ · Cardiovascular Diseases (CVD), Depression Anxiety Disorder	Not applicable	Recruiting	2025-04	China
MRD Monitoring in Lung Cancer After Resection NCT04976296 · ClinicalTrials.gov ↗ · Lung Cancer	Observational	Recruiting	2021-09	China
Scientific Validity Assessment and Optimization of AI-Generated A3/A4 Type Questions for the Chinese Medical Licensing Examination NCT07505862 · ClinicalTrials.gov ↗ · AI (Artificial Intelligence)	Observational	Recruiting	2025-10	China
Pulmonary Watershed Topographic Map Navigation for Lung Nodule Resection NCT06404164 · ClinicalTrials.gov ↗ · Pulmonary Function Assessment, Disease Free Survival, NSCLC, Stage I	Not applicable	Recruiting	2022-01	China
D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC NCT07016126 · ClinicalTrials.gov ↗ · NSCLC (Non-small Cell Lung Cancer)	Phase 3	Recruiting	2024-12	China
Correlation of Microbiome and Metabonomics With IgA Nephropathy NCT05190848 · ClinicalTrials.gov ↗ · IgA Nephropathy	Observational	Recruiting	2020-05	China
A Study of Real-world Events of Vericiguat in Patients With Chronic Kidney Disease and Heart Failure NCT07047547 · ClinicalTrials.gov ↗ · Hemodialysis Complication, Heart Failure Drug: Vericiguat	Not applicable	Recruiting	2025-06	China
A Phase II Single-Arm Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Triple-Negative and HER2+ Breast Cancer Patients NCT06825975 · ClinicalTrials.gov ↗ · Breast Cancers	Not applicable	Not yet open	2025-02	China
A Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Hormone Receptor Positive Breast Cancer Patients NCT06825949 · ClinicalTrials.gov ↗ · Breast Cancers	Not applicable	Not yet open	2025-02	China
This Study Aims to Explore the Efficacy of Hyperbaric Oxygen in the Treatment of Flap Ischaemic Necrosis After Breast Cancer Surgery NCT06811857 · ClinicalTrials.gov ↗ · Flap Necrosis, Flap Ischemia	Not applicable	Not yet open	2025-01	China
Transfusion in Cardiac Valve Surgery NCT06332547 · ClinicalTrials.gov ↗ · Cardiac Surgery With Cardiopulmonary Bypass, Valve Heart Disease	Not applicable	Not yet open	2024-04	China
A Prospective, Non-interventional Cohort Study of Subsolid Pulmonary Nodules NCT06458673 · ClinicalTrials.gov ↗ · Solitary Lung Nodule, Multiple Pulmonary Nodules	Observational	Not yet open	2024-12	China
Safety and Efficacy of Degradable Magnesium Metal Clips in Surgical Margins of Radical Surgery for Malignant Bone and Soft Tissue Tumors NCT06550765 · ClinicalTrials.gov ↗ · Sarcoma, Soft Tissue, Sarcoma, Spindle Cell	Not applicable	Not yet open	2024-08	China
Universal STAR-T Cell Injection in Autoimmune Kidney Diseases NCT07746453 · ClinicalTrials.gov ↗ · IgA Nephropathy (IgAN), Primary Membranous Nephropathy	Not applicable	Not yet open	2026-08	China
Magnesium-L-Threonate Improves Menopausal Symptoms NCT06959745 · ClinicalTrials.gov ↗ · Menopause Syndrome, Magnesium	Not applicable	Not yet open	2025-05	China
Fasting-Mimicking Diet as an Adjunct to Neoadjuvant Chemotherapy for Hormone-Receptor-Positive Breast Cancer NCT07077018 · ClinicalTrials.gov ↗ · Fasting-Mimicking Diet, Breast Cancer, Neoadjuvant Chemotherapy	Not applicable	Not yet open	2025-07	China
Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer NCT07521605 · ClinicalTrials.gov ↗ · Rectal Cancer Patients Drugs: Camrelizumab, Capecitabine, Liposomal Irinotecan	Phase 2	Not yet open	2026-05	China
MRNA Neoantigen Vaccine in Non-Small Cell Lung Cancer NCT06735508 · ClinicalTrials.gov ↗ · NSCLC	Phase EARLY_PHASE1	Not yet open	2025-01	China
Multicenter Prospective Validation of AI Models for Malignancy Risk Prediction in Pulmonary Nodules NCT07727122 · ClinicalTrials.gov ↗ · Pulmonary Nodules	Observational	Not yet open	2026-07	China
Investigation Into the Safety and Efficacy of ICG-Labeled Fluorescence Imaging Technology in Guiding the Resection of Bone and Soft Tissue Tumors NCT06979115 · ClinicalTrials.gov ↗ · Bone Neoplasms, Soft Tissue Neoplasms Drug: Indocyanine Green	Observational	Not yet open	2025-05	China
Efficacy and Safety of Hyperbaric Oxygen Therapy in Improving Nab-paclitaxel-Induced Peripheral Neuropathy NCT07410169 · ClinicalTrials.gov ↗ · Breast Cancer, CIPN - Chemotherapy-Induced Peripheral Neuropathy, Paclitaxel-induced Peripheral Neuropathy	Phase 2/3	Not yet open	2026-01	China
Terbinafine for CSA-AKI Prevention NCT07738328 · ClinicalTrials.gov ↗ · Acute Kidney Injury, Cardiac Surgical Procedures Drug: Terbinafine	Phase 2	Not yet open	2026-09	China
Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial NCT07686796 · ClinicalTrials.gov ↗ · Local Advanced Rectal Cancer, PD-1 Inhibitor, PCSK9 Inhibitor Drugs: Capox, Sintilimab, Tafolecimab	Phase 3	Not yet open	2027-01	China
Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial NCT07486310 · ClinicalTrials.gov ↗ · Advanced Gastric Cancer	Phase 2	Not yet open	2026-03	China
Microbiota in Neoadjuvant Chemoimmunotherapy for NSCLC NCT07752589 · ClinicalTrials.gov ↗ · Non-Small Cell Carcinoma of Lung, Gut Microbiomes, Neoadjuvant Chemoimmunotherapy	Observational	Not yet open	2026-07	China
Hyperbaric Oxygen Therapy for Peripheral Neuropathy Due to Paclitaxel Analogs NCT06819501 · ClinicalTrials.gov ↗ · Breast Cancers	Not applicable	Not yet open	2025-02	China
Guideline-diRected MAnagement for Chronic Kidney Disease: EValuation of an Education Progamme in a National Cluster Randomized Controlled Trial NCT06825676 · ClinicalTrials.gov ↗ · Renal Insufficiency, Chronic, Cardiovascular Diseases (CVD)	Not applicable	Not yet open	2025-03	China
The Effects and Neural Mechanisms of Vitamin D and Iron-Immune Homeostasis on Inhibitory Control in Obsessive-Compulsive Disorder NCT07763977 · ClinicalTrials.gov ↗ · Obsessive Compulsive Disorder (OCD)	Not applicable	By invitation	2024-08	China
Real-World Cohort Study of Cardiopulmonary Function in Chinese Patients With Cardiovascular Disease: CPET Evaluation and Five-Year Prognostic Follow-Up Based on a Multicenter Structured Data Platform NCT07130968 · ClinicalTrials.gov ↗ · MACE, Cardiac Death, Unplanned Repeat Revascularization	Observational	By invitation	2025-02	China
A Randomized Controlled Study of Serplulimab Combined With Chemotherapy for Locally Advanced Gastric Adenocarcinoma NCT07257575 · ClinicalTrials.gov ↗ · Gastric Cancer Stage III Drugs: Docetaxel, Leucovorin, Oxaliplatin	Phase 2	Active, closed	2025-01	China
Efficacy and Safety of HMAs Combined With Venetoclax Versus HMAs Alone in ND Int-and H-risk MDS or CMML NCT07318662 · ClinicalTrials.gov ↗ · MDS, CMML Drug: Venetoclax	Observational	Active, closed	2020-01	China
EFficacy and safEty of cRisugabalin on nocipLastic paIn in Patients With Parkinson's Disease (RELIEF-PD): a Multicentre, Double-blind, Randomised Controlled Trial NCT07483398 · ClinicalTrials.gov ↗ · PARKINSON DISEASE (Disorder) Drug: Crisugabalin	Phase 4	Active, closed	2026-03	China
PCSK9 Inhibitor and PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy for pMMR/MSS Locally Advanced Rectal Cancer NCT06933251 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer (LARC)	Phase 2	Active, closed	2025-04	China
Brolucizumab Efficacy and Safety Single-Arm Descriptive Trial in Patients With Persistent Diabetic Macular Edema NCT06498050 · ClinicalTrials.gov ↗ · Diabetic Macular Edema	Phase 4	Active, closed	2024-07	China
Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC NCT06300424 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, EGFR Gene Mutation Drugs: Almonertinib, Carboplatin, Nab-paclitaxel	Phase 2	Active, closed	2024-04	China
ASPIrin in Reducing Events in Dialysis ( ASPIRED ) NCT04381143 · ClinicalTrials.gov ↗ · CKD (Chronic Kidney Disease) Stage 5D Drug: Aspirin	Phase 4	Active, closed	2020-07	China
A Prospective Observational Study of Changes in Cortisol Levels After Neoadjuvant Immunotherapy and Their Prognostic Value in Patients With NSCLC NCT07530276 · ClinicalTrials.gov ↗ · NSCLC	Observational	Active, closed	2024-08	China
NAC for Treatment-Resistant OCD and Other Related Disorders NCT06956157 · ClinicalTrials.gov ↗ · Obsessive Compulsive Disorder (OCD)	Phase 4	Active, closed	2022-06	China
Induction Lorlatinib in Stage III Non-small Cell Lung Cancer NCT05740943 · ClinicalTrials.gov ↗ · Stage III NSCLC, Surgery Drug: Lorlatinib	Phase 2	Active, closed	2023-03	China
Acute Myocardial Infarction Prediction Using Artificial Intelligence Applied to Electrocardiogram Images NCT07163767 · ClinicalTrials.gov ↗ · Acute Myocardial Infarction (AMI), Electrocardiography, Artifical Intelligence	Observational	Active, closed	2025-08	China
Effectivity and Safety of PFO Closure vs Medicine in Alleviating Migraine NCT04946734 · ClinicalTrials.gov ↗ · PFO - Patent Foramen Ovale, Migraine Drug: Aspirin and clopidogrel	Phase 3	Active, closed	2021-08	China
Preoperative Evaluation of 3D Reconstruction Tool for Nipple-sparing Mastectomy NCT06071234 · ClinicalTrials.gov ↗ · Breast Cancer	Not applicable	Active, closed	2023-10	China
Efficacy of Triple-Combination Therapy in Severe PAH-CHD NCT06196801 · ClinicalTrials.gov ↗ · Congenital Heart Disease, Pulmonary Arterial Hypertension	Observational	Active, closed	2022-06	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Guangdong Provincial People's Hospital trials

48 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 8 more in the trial list above.

Conditions in Guangdong Provincial People's Hospital trials

129 conditions

Breast Cancers4Breast Cancer4 Lung Cancer3Blood Pressure2NSCLC2Obsessive Compulsive Disorder (OCD)2Surgery2 Heart Failure2Cardiovascular Diseases (CVD)2Gastric Cancer Stage III1MDS1CMML1PARKINSON DISEASE (Disorder)1Non-small Cell Lung Cancer1Peritoneal Carcinoma Metastatic1AML, Adult1Minimal Residual Disease1Chronic Kidney Disease1Idiopathic Pulmonary Hypertension1Triple-negative Breast Cancer1Anterior Segment Diseases1HER2-negative Breast Cancer1 Advanced Breast Cancer1 Soft Tissue Sarcoma1

By trial register

Register	Trials	Recruiting
Clinical trials in China	84	48

A trial with sites in more than one country appears in each of those registers.

Questions about Guangdong Provincial People's Hospital trials

How many clinical trials does Guangdong Provincial People's Hospital sponsor?

Guangdong Provincial People's Hospital is the lead sponsor of 84 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Guangdong Provincial People's Hospital trials recruiting?

Yes. 48 of its 84 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Guangdong Provincial People's Hospital testing?

Its current trials name 48 drugs and biologicals as interventions. The most frequent are Carboplatin (4), Capecitabine (3), Aspirin (2), Nab-paclitaxel (2) and Sintilimab (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Guangdong Provincial People's Hospital clinical trials